Floatz logo

Pomalidomide

Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease

National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 1/2CCC
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 1/2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 1/2CCC
Inno-206
National Cancer Institute (NCI)
Phase 1/2CCC
ETOPOSIDE
National Cancer Institute (NCI)
Phase 1/2CCC
Cyclophosphamide
National Cancer Institute (NCI)
Phase 1/2CCC

Same molecule, other indications

Pomalidomide is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
63 / 100
View asset →
AmyloidosisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →